[Federal Register Volume 83, Number 118 (Tuesday, June 19, 2018)]
[Notices]
[Pages 28446-28447]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13061]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical CBRN Defense Consortium
Notice is hereby given that, on May 14, 2018, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. Sec. 4301 et seq. (``the Act''), Medical CBRN Defense
Consortium (``MCDC'') has filed written notifications simultaneously
with the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Spero Therapeutics, Inc., Cambridge, MA; DCN Diagnostics,
Carlsbad, CA; Silver Lake Research
[[Page 28447]]
Corporation, Azusa, CA; Coagulant Therapeutics, Mill Valley, CA; Duke
University, Durham, NC; International AIDS Vaccine Initiative (IAVI),
New York, NY; AN2 Therapeutics, Inc., Menlo Park, CA; University of
Nevada Reno, Reno, NV; New Mexico Institute of Mining and Technology,
Socorro, NM; VecTOR Test Systems, Inc., Thousand Oaks, CA; The Regents
of the University of California, Irvine, Irvine, CA; The Wistar
Institute, Philadelphia, PA; Chenega Support Services, LLC, San
Antonia, TX; PlantVax Inc., Rockville, MD; Binergy Scientific, Inc.,
Atlanta, GA; Zeteo Tech, Inc., Sykesville, MD; The Regents of
University of New Mexico, Health Sciences Center, Albuquerque, NM;
Rubicon Biotechnology, Lake Forest, CA; Innovative Emergency
Management, Inc. (IEM), Arlington, VA; Macromoltek, Austin, TX; Paratek
Pharmaceuticals, Boston, MA; Terminal Horizon Operations and
Resourcing, Inc. (THOR), St. Petersburg, FL; Phosphorex Inc.,
Hopkinton, MA; Celina Tent, Inc., Celina, OH; Medinstill Development
LLC, New Milford, CT; BioHybrid Solutions LLC, Pittsburgh, PA;
GeneCapture Inc., Huntsville, AL; University of Arizona (Arizona Board
of Regents), Tucson, AZ; Peregrine Technical Solutions, LLC, Yorktown,
VA; and DxDiscovery, Inc., Reno, NV, have been added as parties to this
venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MCDC intends to file additional
written notifications disclosing all changes in membership.
On November 13, 2015, MCDC filed its original notification pursuant
to Section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to Section 6(b) of the Act on
January 6, 2016 (81 FR 513).
The last notification was filed with the Department on January 16,
2018. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on February 27, 2018 (83 FR 8506).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2018-13061 Filed 6-18-18; 8:45 am]
BILLING CODE 4410-11-P